VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

• Status: Completed
• Trial end date: 2006-01-10
• Target enrollment: 0
• Participant gender: All

Summary

Eligible subjects will be randomized to receive VALTREX® tablet 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days between treatment periods.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Valacyclovir

Criteria

Inclusion Criteria:

• In overall general good health.

• HSV-2 (Herpes Simplex Virus-2) seropositive at screening.

Exclusion criteria:

• have active lesions consistent with genital herpes.

• previous history of symptomatic genital herpes.

• history of recurrent, undiagnosed symptoms consistent with genital herpes.